CollPlant Biotechnologies Management
Management criteria checks 3/4
CollPlant Biotechnologies' CEO is Yehiel Tal, appointed in Jan 2010, has a tenure of 16.08 years. total yearly compensation is $1.01M, comprised of 53.4% salary and 46.6% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth €18.88K. The average tenure of the management team and the board of directors is 14.1 years and 5.7 years respectively.
Key information
Yehiel Tal
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 53.41% |
| CEO tenure | 16.1yrs |
| CEO ownership | 0.2% |
| Management average tenure | 14.1yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$12m |
| Jun 30 2025 | n/a | n/a | -US$13m |
| Mar 31 2025 | n/a | n/a | -US$14m |
| Dec 31 2024 | US$1m | US$540k | -US$17m |
| Sep 30 2024 | n/a | n/a | -US$17m |
| Jun 30 2024 | n/a | n/a | -US$17m |
| Mar 31 2024 | n/a | n/a | -US$7m |
| Dec 31 2023 | US$1m | US$541k | -US$7m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | -US$7m |
| Mar 31 2023 | n/a | n/a | -US$17m |
| Dec 31 2022 | US$1m | US$689k | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$16m |
| Jun 30 2022 | n/a | n/a | -US$15m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | US$1m | US$422k | US$237k |
| Sep 30 2021 | n/a | n/a | US$1m |
| Jun 30 2021 | n/a | n/a | US$5m |
| Mar 31 2021 | n/a | n/a | US$6m |
| Dec 31 2020 | US$761k | US$391k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$11m |
| Mar 31 2020 | n/a | n/a | -US$11m |
| Dec 31 2019 | US$784k | US$395k | -US$11m |
Compensation vs Market: Yehiel's total compensation ($USD1.01M) is above average for companies of similar size in the German market ($USD360.87K).
Compensation vs Earnings: Yehiel's compensation has been consistent with company performance over the past year.
CEO
Yehiel Tal (73 yo)
Mr. Yehiel Tal has been the Chief Executive Officer of CollPlant Biotechnologies Ltd. (formerly known as CollPlant Holdings Ltd.) since January 2010 and also serves as its Director since May 2022 and is In...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Interim Chairman | 16.1yrs | US$1.01m | 0.22% € 18.9k | |
| Deputy CEO & CFO | 14.1yrs | US$752.00k | no data | |
| Vice President of Operations | 2.8yrs | US$432.00k | no data | |
| Founder & Chief Scientist | 22.1yrs | US$252.97k | no data | |
| Vice President of Legal Affairs | no data | no data | no data | |
| Vice President of Human Resources | 4.9yrs | no data | no data |
Experienced Management: CPT's management team is seasoned and experienced (14.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Interim Chairman | 3.8yrs | US$1.01m | 0.22% € 18.9k | |
| Independent Director | 9.8yrs | no data | no data | |
| Independent Director | 8.1yrs | no data | no data | |
| Independent Director | 4.9yrs | no data | 2.62% € 228.9k | |
| Member of the Scientific Advisory Board & Member of the Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 6.5yrs | no data | no data | |
| Independent Director | 4.5yrs | no data | no data | |
| Member of Advisory Board | 7.7yrs | no data | no data | |
| Member of Advisory Board | 2.1yrs | no data | no data | |
| Member of Advisory Board | no data | no data | no data |
Experienced Board: CPT's board of directors are considered experienced (5.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/15 11:37 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CollPlant Biotechnologies Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Linda Pomeroy | Edison Investment Research |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |